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Abstract
 
In humans, the elderly and immunocompromised are at greatest risk for disseminated West
Nile virus (WNV) infection, yet the immunologic basis for this remains unclear. We demon-
strated previously that B cells and IgG contributed to the defense against disseminated WNV
infection (Diamond, M.S., B. Shrestha, A. Marri, D. Mahan, and M. Engle. 2003. 
 
J. Virol.
 
 77:
2578–2586). In this paper, we addressed the function of IgM in controlling WNV infection.
C57BL/6J mice (sIgM
 
 
 
/
 
 
 
) that were deficient in the production of secreted IgM but capable
of expressing surface IgM and secreting other immunoglobulin isotypes were vulnerable to
lethal infection, even after inoculation with low doses of WNV. Within 96 h, markedly higher
levels of infectious virus were detected in the serum of sIgM
 
 
 
/
 
 
 
 mice compared with wild-type
mice. The enhanced viremia correlated with higher WNV burdens in the central nervous system,
and was also associated with a blunted anti-WNV IgG response. Passive transfer of polyclonal
anti-WNV IgM or IgG protected sIgM
 
 
 
/
 
 
 
 mice against mortality, although administration of
comparable amounts of a nonneutralizing monoclonal anti-WNV IgM provided no protection.
In a prospective analysis, a low titer of anti-WNV IgM antibodies at day 4 uniformly predicted
mortality in wild-type mice. Thus, the induction of a specific, neutralizing IgM response early
in the course of WNV infection limits viremia and dissemination into the central nervous system,
and protects against lethal infection.
Key words: ﬂavivirus • antibody • innate immunity • encephalitis • risk factor
 
Introduction
 
West Nile virus (WNV) is a single-stranded positive-polarity
RNA virus and the etiologic agent of West Nile encephalitis.
WNV is maintained in a natural cycle between mosquitoes
and birds but also infects humans, horses, and other animals.
It is endemic in parts of Africa, Europe, the Middle East,
and Asia (1), and outbreaks are now occurring annually in
North America (2). Humans develop a febrile illness with a
subset of cases progressing to a meningitis or encephalitis
syndrome (1). Currently, no specific therapy or vaccine has
been approved for human use.
Host factors influence the expression of WNV disease in
humans (3). Infants, the elderly, and those with impaired
immune systems are at greatest risk for severe neurological
disease (1, 4, 5). Similarly, in animals, the maturation and
integrity of the immune system correlates with resistance to
WNV infection (6–8). Through the use of animal models
of WNV infection, the immunologic basis for protection is
beginning to be understood (9). T and B lymphocytes protect
against WNV infection: SCID and 
 
RAG1
 
 mice (T and B
cell–deficient; references 10, 11) and B cell–deficient mice
uniformly succumb to WNV infection (11). Macrophages
also have important functions because their depletion in-
creased the neuroinvasiveness of an attenuated strain (12).
Humoral immunity is an essential component of the
immune response to WNV and other flaviviruses because
neutralizing antibodies limit dissemination of infection.
The role of immune IgG in protection has been studied
extensively in mouse models of flavivirus infection, includ-
 
Address correspondence to Michael S. Diamond, Washington University
School of Medicine, 660 S. Euclid Ave., Box 8051, St. Louis, MO
63110. Phone: (314) 362-2842; Fax: (314) 362-9230; 
email: diamond@borcim.wustl.edu
 
Abbreviations used in this paper:
 
 CNS, central nervous system; PRNT,
plaque reduction neutralization titer; WNV, West Nile virus. 
IgM Limits Dissemination of WNV Infection
 
1854
ing WNV. Passive transfer of polyclonal or monoclonal
IgG before infection protects mice against lethal flavivirus
challenge (11, 13–21). Immune IgG are speculated to pro-
tect against WNV infection by direct neutralization of re-
ceptor binding, through Fc-receptor–dependent viral clear-
ance, by complement-mediated lysis of virus or infected
cells, and by antibody-dependent cytotoxicity. The impor-
tance of antibodies in the protection against WNV infec-
tion has been highlighted by recent studies in antibody-
deficient mice (11). Mice lacking antibodies developed
encephalitis after infection with WNV; high levels of virus
and viral RNA were detected both peripherally and in the
central nervous system (CNS).
The function of IgM against WNV or other flaviviruses
is less well characterized. Low levels of serum IgM anti-
body against Japanese Encephalitis virus were an indepen-
dent risk factor for severe neurological deficit in humans
(22). Our own studies with B cell–deficient mice demon-
strated a 
 
 
 
500-fold increase in viremia 4 d after infection, a
time when only immune IgM was detected in the serum
from wild-type mice (11). Because passive transfer of im-
mune IgM against WNV, derived from wild-type mice 4 d
after infection, prolonged survival of B cell–deficient mice
and completely protected wild-type mice, natural or in-
duced IgM could limit WNV infection by controlling vire-
mia and/or by triggering an adaptive B or T cell response
(23, 24).
Natural and induced IgM antibodies against WNV may
have important protective functions against WNV. Natural
IgM is secreted constitutively by CD5
 
 
 
 B-1 cells without
specific stimulation, has widely variable binding avidities
(10
 
 
 
3
 
–10
 
 
 
11
 
 M), and represents an initial defense against
pathogens (25–27). IgM mediates direct neutralization of
some bacteria and viruses in circulation (26, 28, 29), en-
hances phagocytosis of pathogens (30), and activates com-
plement (27, 31, 32) to prime the immune response. IgM
antibody–antigen complexes are efficiently filtered in the
spleen and lymph nodes and may diminish hematogenous
spread and infection of critical end organ targets such as the
brain or spinal cord (24). In this work, we directly assessed
the function of secreted IgM in limiting WNV infection.
C57BL/6J mice that did not produce secreted IgM (27, 33,
34) uniformly succumbed to WNV infection. Infection in
these mice resulted in higher levels of viremia and CNS vi-
ral burdens. Passive transfer of induced, but not natural,
IgM protected sIgM
 
 
 
/
 
 
 
 mice against lethal WNV infec-
tion, but administration of a nonneutralizing IgM mono-
clonal antibody did not improve outcome. A low titer of
anti-WNV IgM antibodies at day 4 after infection in wild-
type mice uniformly predicted mortality. Thus, the induc-
tion of neutralizing anti-WNV IgM early in the immune
response blunts viremia and the spread of infection and is
required for survival.
 
Materials and Methods
 
Cells, Viruses, and Antibodies. 
 
BHK-21 and C6/36 
 
Aedes al-
bopictus
 
 cells were cultured as described previously (35, 36). The
WNV strain (3000.0259) was isolated in New York in 2000 (37)
and obtained from L. Kramer (New York State Department of
Health, Albany, NY
 
).
 
 All cell culture and in vivo studies used a
stock (2 
 
 
 
 10
 
8
 
 PFU/ml) of this virus that was propagated (passage
1) once in C6/36 cells. Viruses were diluted in HBSS and 1%
heat-inactivated FBS for injection into mice. Hybridoma cells
that produce monoclonal antibodies against WNV envelope pro-
tein (4G2, IgG2a; reference 38; H5.46, IgM; reference 39) were
cultured in DMEM supplemented with 10% FBS. H5.46 is a
monoclonal IgM antibody that binds to the E protein of WNV
and was used from ascites fluid (39).
 
Mouse Experiments. 
 
All mice used in these experiments were
derived from or backcrossed onto the inbred C57BL/6J strain.
Mice that lack the ability to secrete IgM due to a targeted muta-
tion that disrupts expression of the secreted but not membrane
form of IgM have been described previously (33) and were ob-
tained from M. Carroll (The Center for Blood Research, Harvard
Medical School, Boston, MA) and J. Chen (Massachusetts Insti-
tute of Technology, Cambridge, MA). The wild type C57BL/6J
was purchased from Jackson ImmunoResearch Laboratories.
8–12-wk-old mice were used for all studies and inoculated sub-
cutaneously with WNV by footpad injection after anesthetization
with xylazine and ketamine. In some experiments, mice were
phlebotomized (0.2 ml of blood) at day 4 after infection. Mouse
experiments were approved and performed according to the
guidelines of the Washington University School of Medicine An-
imal Safety Committee. Differences in survival times and out-
come were assessed by the Kaplan-Meier analysis and the log-
rank test.
 
Passive Antibody Transfer Experiments. 
 
Serum was isolated
from naive or infected (day 4 after infection) mice, heat-inacti-
vated for 30 min at 56
 
 
 
C, and stored at 
 
 
 
80
 
 
 
C. An aliquot was
reserved to confirm levels of specific IgM against WNV. Ascites
fluid that contained the H5.46 anti-WNV IgM monoclonal anti-
body was heat-inactivated, and diluted in HBSS with 1% heat-
inactivated FBS. For passive transfer experiments, mice were ad-
ministered 0.5 ml of serum or H5.46 antibody intraperitoneally
1 d before and after inoculation with 10
 
2
 
 PFU of WNV. Purified
human 
 
 
 
-globulin with reactivity against WNV was obtained
commercially (I. Nur, Omrix Biopharmaceuticals Ltd, Kiryat
Ono, Israel) from a WNV endemic region (Israel) that has had re-
peated outbreaks in recent years. Several batches of pooled hu-
man 
 
 
 
 globulin (50 mg/ml IgG) were obtained and tested posi-
tive by ELISA against WNV antigens and by plaque reduction
neutralization titer (PRNT) assay (11, 40). 50 mg/ml IgG nega-
tive human 
 
 
 
 globulin was obtained from a nonendemic region
(Midwestern United States, 2000); purified preparations lacked
immune antibodies as judged by ELISA and PRNT assays. In ex-
periments with human 
 
 
 
 globulin, mice were administered a sin-
gle dose of immune or nonimmune purified IgG by intraperito-
neal injection at the same time as footpad inoculation of WNV.
 
Quantitation of Viral Burden in Mice. 
 
For analysis of virus in
tissues of infected mice, organs were recovered after cardiac per-
fusion with PBS and dissection, cooled on ice, weighed, homog-
enized using a Bead-beater apparatus (BioSpec Products, Inc.),
and titrated for virus by plaque assay on BHK-21 cells as de-
scribed previously (11, 36). Serum was obtained from whole
blood by phlebotomy of the axillary vein immediately before be-
ing killed.
 
Quantitation of Antibodies. 
 
The titer of neutralizing antibod-
ies was determined by a standard plaque-reduction neutralization
assay (11, 41). Experiments were performed in duplicate and
plaques were scored visually. Results were plotted and the 
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PRNT for 50% inhibition (PRNT
 
50
 
) was determined. In some
experiments, IgM was depleted by immunologic means (11). Se-
rum or diluted ascites were incubated twice with an equal vol-
ume of anti-IgM–specific agarose for 1 h at 4
 
 
 
C. After centrifuga-
tion, the supernatant (1:4 dilution of original sample) was titrated
for PRNT. ELISA confirmed isotype depletion.
The overall titer of antibodies was determined using an ELISA
assay against purified WNV antigen. In brief, soluble WNV E
protein that was generated from baculovirus-infected SF9 cells
(unpublished data) was adsorbed overnight at 4
 
 
 
C to microtiter
plates (Maxi-Sorp; Nunc). Nonspecific binding was blocked af-
ter incubation with blocking buffer (PBS, 0.05% Tween 20, 3%
BSA, and 3% horse serum) for 1 h at 37
 
 
 
C. Plates were incu-
bated with serial dilutions of heat-inactivated serum from in-
fected mice for 1 h at 4
 
 
 
C. After extensive washing, plates were
incubated with biotin-conjugated goat anti–mouse IgG (Sigma-
Aldrich) and horseradish peroxidase–conjugated streptavidin
(Sigma-Aldrich) at 4
 
 
 
C, and developed after the addition of tet-
ramethylbenzidine substrate (Sigma-Aldrich). Optical densities
were determined with an automatic ELISA plate reader at 450
nm (Molecular Devices). Optical densities that were twice back-
ground (0.06–0.075) binding to BSA were considered positive.
The quantitation of antibodies by isotype was performed simi-
larly with some modifications. Serum was obtained from wild-
type or sIgM
 
 
 
/
 
 
 
 mice at day 10 after infection was used at a
standard 1:40 dilution. Dilutions of isotype-specific antibodies
(Southern Biotechnology Associates, Inc.) at a previously opti-
mized concentration (1:2,000–1:4,000) were used. Optical den-
sities were measured at 450 nm, and after subtraction of back-
ground binding, a value for each isotype was obtained and
directly compared.
 
Statistical Analyses. 
 
For survival analysis, Kaplan–Meier sur-
vival curves were plotted using Prism software (GraphPad). Mor-
tality curves were analyzed by the log rank test and average sur-
vival times were evaluated using the Mann-Whitney test.
 
Results
 
Decreased Survival of sIgM
 
   
 
 Mice after Infection with WNV
 
Previous studies in our laboratory with B cell–deficient
 
 
 
MT C57BL/6J mice indicated that B cells and antibody
had a critical function in preventing the dissemination of
WNV into the CNS. Because a 500-fold difference in vire-
mia between 
 
 
 
MT and congenic wild-type mice was ob-
served within 4 d of infection, a time when only specific
IgM against WNV was detected in the serum of wild-type
mice, we postulated that newly generated anti-WNV IgM
limited infection. To address this directly, we compared
WNV infection in wild-type and congenic sIgM
 
 
 
/
 
 
 
C57BL/6 mice that lack the ability to secrete IgM, but re-
tain a membrane form of IgM and the ability to class switch
and secrete IgG (33). Our previously described mouse
model of infection was used in which a low passage WNV
isolate was inoculated subcutaneously into the footpad of
adult mice to mimic natural infection and facilitate an anal-
ysis of viral replication and spread (11). After infection with
10
 
2
 
 PFUs of WNV, 
 
 
 
70% of adult wild-type mice sur-
vived (Fig. 1). All animals showed clinical evidence of in-
fection with fur ruffling, hunchback posture, and weight
loss (unpublished data). In contrast, infection with 10
 
2
 
 PFU
of WNV resulted in 100% mortality of the sIgM
 
 
 
/
 
 
 
 mice
(P 
 
 
 
 0.0001). Similar results were observed with a higher
(10
 
6
 
 PFU) dose of WNV (unpublished data).
 
Increased Viral Load in sIgM
 
   
 
 Mice
 
To begin to understand the mechanism by which a defi-
ciency in secreted IgM made mice vulnerable to infection
by WNV, the levels of infectious virus were measured
from serum, spleen, kidney, brain, and spinal cord using
plaque assays (11, 42). A time course was performed in
wild-type and sIgM
 
 
 
/
 
 
 
 mice after inoculation with 10
 
2
 
PFU to determine the effect of IgM against WNV on the
kinetics and magnitude of infection (Fig. 2).
 
Viremia. 
 
In wild-type mice, viremia was below the
level of detection by infectious plaque assay throughout the
time course. In contrast, 10
 
3
 
–10
 
4
 
 PFU/ml of infectious vi-
rus was detectable in sIgM
 
 
 
/
 
 
 
 mice between days 4 and 6
after infection (Fig. 2 A, P 
 
 
 
 0.001), and subsequently
waned to levels below detection. However, when viral
RNA in serum was measured by a more sensitive fluoro-
genic RT-PCR assay (11, 42), additional information was
obtained (Fig. 2 B). At day 2 after infection, similar levels
of WNV RNA were detected (
 
 
 
5,000 copies of WNV
RNA/ml) in both wild-type and sIgM
 
 
 
/
 
 
 
 mice. At day 4
after infection, a time when anti-WNV IgM was first ob-
served in the serum of wild-type mice (11), sIgM
 
 
 
/
 
 
 
 mice
had 50-fold higher levels of WNV RNA in serum (P 
 
 
 
0.01). By day 6, WNV RNA was no longer detected in the
serum of wild-type mice; in contrast, 
 
 
 
10
 
6
 
 copies/ml were
observed in serum from sIgM
 
 
 
/
 
 
 
 mice. By day 8, a time
when immune IgG was first measured at significant levels
(see Fig. 3); only low levels (
 
 
 
100 copies WNV RNA/ml)
were detected in the serum of sIgM
 
 
 
/
 
 
 
 mice. Collectively,
these studies suggest that a lack of development of specific
IgM after WNV infection results in a delayed clearance of
virus from serum.
 
Spleen and Kidney. 
 
In spleens from both wild-type and
sIgM
 
 
 
/
 
 
 
 mice, similar kinetics of WNV accumulation were
Figure 1. Survival data for C57BL/6J mice inoculated with WNV.
Wild-type and sIgM    mice were inoculated via footpad with the indicated
doses of WNV and followed for 28 d. The survival curves were con-
structed using data from three to five separate experiments. The number
of animals were n   28 for wild-type mice and n   24 for sIgM /  mice.
The mean survival times (in days) were 21.8   1.6 for wild-type and
9.8   0.1 for sIgM    mice (P   0.0001). 
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observed (Fig. 2 C). Virus levels peaked in the spleen at day
4 after infection, decreased by day 6, and were absent at day
8. Although there was no significant difference in viral bur-
den at day 4 after infection (
 
 
 
10
 
4
 
 PFU/g; P 
 
 
 
 0.3), there
was a small yet significant increase in virus production in the
spleens of sIgM
 
 
 
/
 
 
 
 mice at day 6 after infection (
 
 
 
10
 
4
 
 com-
pared with 10
 
3
 
 PFU/g; P 
 
 
 
 0.01). In contrast, a distinct
pattern of WNV infection was observed in a different pe-
ripheral organ, the kidney (Fig. 2 D). In wild-type mice,
kidney viral burdens were below the level of detection by
direct plaque assay at all times measured. However, 
 
 
 
10
 
3
 
–
10
 
4
 
 PFU of virus was detected in kidneys from sIgM
 
 
 
/
 
 
 
mice at days 6 and 9 after initial infection (P 
 
 
 
 0.00001).
 
CNS. 
 
The kinetics of CNS dissemination between
wild-type and sIgM /  mice began similarly. Infectious vi-
rus was first detected in the brain at day 6 and in the spinal
cord at day 8 after infection in wild-type and sIgM /  mice
(Fig. 2, E and F). However, by 8 d after infection, sIgM / 
mice had from 10- to 20-fold higher levels of infectious vi-
rus in the brain and spinal cord (P   0.04), and by day 10,
100-fold higher levels of WNV were measured in the
brains of sIgM /  mice. The difference of CNS viral load
between wild-type and sIgM /  mice was not explained
by the bias of the survival curves because, by day 10, no in-
dividual wild-type mouse that was morbidly infected had
viral titers in the brain that approached those in the sIgM / 
mice (e.g., maximum wild-type brain titer, 2.1    104
PFU/g; unpublished data).
IgG Response against WNV in sIgM    Mice 
IgM is believed to have an important role in triggering
the adaptive immune response (24) as mice that lacked se-
creted IgM had blunted IgG responses after inoculation with
influenza virus (27) or protein antigens (33). To determine
whether a deficiency of secreted IgM affected the IgG re-
sponses against WNV, an ELISA against purified WNV en-
velope protein was used to measure serum levels of anti-
WNV IgG in wild-type and sIgM /  mice after inoculation
Figure 2. WNV burden in
peripheral and CNS tissues of
adult wild-type and sIgM   
C57BL/6J mice. (A) Infectious
virus levels in serum. Serum was
harvested at the indicated days
after subcutaneous footpad inoc-
ulation with 102 PFU of WNV
and virus levels were measured
using a viral plaque assay in
BHK21 cells. Data are shown as
the mean of PFU per milliliter of
serum and reflect from 6 to 10
mice per time point. The dotted
line represents the limit of sensi-
tivity of the assay. (B) WNV
RNA levels in serum. Viral
RNA levels were determined
from serum of wild-type or
sIgM    mice after WNV infec-
tion at the indicated days using a
real-time fluorogenic RT-PCR
assay. Data are expressed as geno-
mic equivalents of WNV RNA
per milliliter of serum and reflect
the mean of five independent
mice per time point. (C) Infec-
tious virus levels in the spleen.
Virus levels were determined
from spleen homogenates by
plaque assay and normalized for
the weight of the tissue sample.
Data are the mean of 10 animals
per time point. (D) Infectious
virus levels in the kidney. Virus
levels were determined from
kidney homogenates by plaque
assay and normalized for the
weight of the tissue sample. Data
are the mean of 10 kidneys per
time point. (E and F) Infectious
virus levels in the CNS. Virus
levels were determined from spinal
cord (E) or brain (F) as described
in Fig. 2 C.Diamond et al. 1857
with WNV. In agreement with our previous work (11),
wild-type mice developed a specific anti-WNV IgM re-
sponse that was detectable within 4 d of infection, and as ex-
pected, there was no specific IgM detected in the sIgM / 
mice (unpublished data). No specific IgG against WNV was
detected in either wild-type or sIgM /  mice until 8 d after
infection. The sIgM /  mice responded to WNV infection
but the overall levels of virus-specific IgG were reduced
compared with wild-type controls at days 8 and 10 after in-
fection (Fig. 3). Isotype-specific analysis revealed markedly
lower levels of IgG2b in sIgM /  mice (unpublished data).
The results of these experiments suggest that secreted IgM
that is generated after WNV infection may trigger an ampli-
fied IgG response that facilitates clearance of virus.
Role of Natural and Induced IgM in WNV Protection
Although our studies demonstrated that sIgM /  mice
were vulnerable to WNV infection, the nature of the pro-
tective IgM response remained unclear. We wished to dis-
tinguish the protective function of natural and induced
IgM. Natural IgM is constitutively secreted by CD5  B-1
cells without specific stimulation, has widely variable bind-
ing avidities (10 3–10 11 M), and represents an initial de-
fense against pathogens (25–27). Induced IgM is secreted
after antigen-specific stimulation in the lymph node or
spleen; depending on the antigen, this process may occur
in a T cell–dependent or T cell–independent manner. Nat-
ural and induced IgM may directly neutralize pathogens
(26, 28), facilitate clearance via phagocytosis (30), and acti-
vate complement (27) to prime the immune response (24,
43). To address the protective nature of natural and in-
duced IgM, sIgM /  mice were passively administered
pooled heat-inactivated serum collected from naive wild-
type mice (natural IgM) or mice that were exposed to
WNV for 4 d (induced IgM); at this early juncture, serum
contains low levels of neutralizing IgM (Table I) but no
specific IgG (reference 11 and unpublished data). sIgM / 
mice were inoculated with 0.5 ml of heat-inactivated sera
1 d before and after infection with 102 PFU of WNV (Fig.
4 A). Although similar quantities of naive serum (i.e., natu-
ral IgM) protected sIgM /  mice against infection with in-
fluenza virus (27) and vesicular stomatitis virus (26), it had
no significant effect on mortality or average survival time
(P   0.4) after WNV infection. In contrast, passive admin-
istration of 1.0 ml of heat-inactivated serum that contained
induced IgM, but not IgG, provided almost complete pro-
tection against infection with 102 PFU of WNV (Fig. 4 A,
P   0.0002). Chemical and immunologic depletion exper-
iments confirmed that IgM was responsible for the protec-
tive effect (reference 11 and unpublished data). The results
of the reconstitution experiments with sIgM /  mice con-
trasted with B cell–deficient mice in which induced IgM
increased average survival time but did not diminish
WNV-induced mortality (11). In parallel experiments, pas-
sive transfer of purified polyclonal human anti-WNV IgG
protected wild-type, B cell–deficient, and sIgM /  mice
against lethal WNV challenge (Fig. 4 B; reference 40). Al-
though natural IgM may function in the initial priming of
the immune response against WNV, by itself, it cannot
sustain control of WNV infection. In contrast, induced
IgM, which is produced within the first few days of infec-
tion, slows the dissemination of WNV temporarily until an
adaptive T and B cell response is produced.
Figure 3. Development of specific IgG against WNV. Serum was
collected from wild-type or sIgM    mice at the indicated days after infec-
tion. The levels of specific IgG were determined by incubating serum
with adsorbed control or purified WNV E protein. Data are the mean of
serum from 8 to 12 mice per time point performed in duplicate. p-values
and statistical significance are as indicated.
Figure 4. Passive administra-
tion of serum or purified anti-
bodies to sIgM    mice. (A)
Serum was collected from naive
mice, or mice that were in-
fected with WNV for 4 d. After
heat-inactivation, 0.5 ml of serum
was administered to sIgM   
mice 1 d before and after infec-
tion with 102 PFU of WNV.
Data reflect two independent
experiments with five mice per
condition, and p-values are in-
dicated next to each curve. (B)
10 mg of purified human immune
or nonimmune IgG were ad-
ministered as a single dose via an intraperitoneal route immediately before administration of 102 PFU of WNV via footpad inoculation. Data are
from two independent experiments with five mice per condition, and p-values are indicated next to each curve.IgM Limits Dissemination of WNV Infection 1858
The Role of Neutralizing IgM in Protection
Because the absence of secreted IgM resulted in in-
creased viremia at day 4, we speculated that induced IgM
might limit WNV infection by neutralizing virus before
the development of an adaptive IgG response. As men-
tioned, pooled serum that was obtained from mice at 4 d
after infection contained neutralizing IgM (PRNT50  
1/30) and conferred protection; the neutralizing activity
could be precleared with anti-IgM but not anti-IgG Sepha-
rose (Table I; reference 11). To assess whether neutralizing
activity of IgM was required for protection, we passively
transferred H5.46, a monoclonal IgM antibody that recog-
nized the E protein of WNV (39) and lacked neutralizing
activity (Table I). An ELISA assay against purified E pro-
tein confirmed that similar, if not greater, amounts of the
H5.46 antibody were administered. Interestingly, passive
transfer of either dilution (1:10 and 1:40 of ascites) of
H5.46 anti-WNV IgM to sIgM /  mice did not alter the
survival time, mortality rate, or viral burden in peripheral
or CNS compartments when compared with untreated
controls (Table I and unpublished data). Thus, for protec-
tion to be transferred, anti-WNV IgM required neutraliz-
ing activity.
The IgM Response against WNV as a Predictor of Survival
Because a genetic deficiency of secreted IgM was associ-
ated with lethality after WNV infection, we questioned
whether variability in anti-WNV IgM levels correlated
with survival in wild-type animals. To address this, 7-wk-
old wild-type C57BL/6J mice were infected with 102 PFU
of WNV. At 4 d after infection, mice were phlebotomized
(0.2 ml of blood) and followed prospectively for survival,
and the serum was analyzed for anti-WNV IgM levels by
an isotype-specific ELISA against affinity-purified recombi-
nant WNV E protein (Fig. 5). Mice that survived had anti-
WNV IgM titers of  1:45 at day 4 after infection. In con-
trast, all mice died that had anti-WNV IgM titers  1:25 at
day 4 after infection. Thus, the presence of a low titer of
anti-WNV IgM early in the course of WNV infection uni-
formly predicted mortality.
Discussion
We demonstrated previously that antibody played a criti-
cal role in preventing the dissemination of WNV into the
CNS (11). Because B cell–deficient mice that lacked anti-
bodies demonstrated a  500-fold increase in viremia 4 d af-
ter infection, a time when only immune IgM was detected
in the serum from wild-type mice, we postulated a critical
role for IgM in controlling the early phases of WNV infec-
tion. In this paper, we directly addressed the function of se-
creted IgM in limiting the spread of WNV infection.
C57BL/6J sIgM /  mice that were deficient in the produc-
tion of secreted IgM but capable of secreting other immu-
Table I. Correlation of Anti-WNV IgM Neutralization Activity 
with Protection against WNV Infection
ELISA Binding Activity to Purified E Proteina
1:33 1:100 1:300
Day 4 serum after infection (pooled) 0.251  0.103 NS
H5.46 monoclonal IgM (1:10 ascites)  0.505  0.330 0.210
H5.46 monoclonal IgM (1:40 ascites)  0.325  0.254 0.125
Neutralizing Titers (PRNT50)b
No
treatment
IgM
preclear
Day 4 serum after infection (pooled) 1:30 ND
H5.46 monoclonal IgM (1:10 ascites)  ND NT
Protection of sIgM    Mice with Anti-IgM 
Antibody Reconstitutionc
Survival at 21 d
Day 4 serum after infection (pooled, 1 ml) 90% (n   10)
H5.46 monoclonal IgM (1:10 ascites, 1 ml)  0% (n   10)
H5.46 monoclonal IgM (1:40 ascites, 1 ml)  0% (n   10)
No antibody 0% (n   6)
aAn ELISA assay against solid phase purified WNV E protein was per-
formed with the indicated dilutions of polyclonal or monoclonal IgM
against WNV. Optical density readings are given for one representative
experiment of two performed in duplicate. NS, not significant.
bNeutralizing titers were determined by plaque reduction assay in
BHK21 cells. No treatment indicates that the diluted heat-inactivated
serum or ascites were mixed directly with 100 PFU of WNV. IgM pre-
clear indicates that serum or ascites were precleared with anti-IgM
Sepharose before the plaque reduction assay. Results are representative
of three independent experiments. ND, none detected; NT, not tested.
c0.5 ml of heat-inactivated day 4 serum or H5.46 monoclonal IgM
(1:10 or 1:40 dilution of ascites) was given intraperitoneally to sIgM / 
1 d before and after subcutaneous infection with 102 PFU of WNV.
Results were obtained from two independent experiments.
Figure 5. Scatter plot of the relationship between specific anti-WNV
IgM titer at day 4 after infection and survival. 7-wk-old wild-type mice
were infected with 102 PFU of WNV. At day 4 after infection, animals
were phlebotomized and followed clinically for survival. An ELISA was
used to evaluate serum for specific IgM titer against purified WNV E protein
using a biotin-conjugated goat anti–mouse IgM secondary antibody. 20
animals were included in the study. 8 survived and 12 died after infection.
Five of the animals that died had identical titers of 1:5. Solid lines indicate
the mean titer.Diamond et al. 1859
noglobulin isotypes were highly vulnerable to lethal infec-
tion even after infection with low doses of WNV.
To our knowledge, this is the first paper to show a defin-
itive protective role for secreted IgM against flavivirus in-
fection. Although previous papers have demonstrated that
passive administration of IgG or immune serum prevents
encephalitis caused by flaviviruses (11, 13, 14, 21, 44–46)
and nonflaviviruses (47–54), none demonstrated a defini-
tive role for IgM. Induced IgM does have an important
protective role against other pathogens. An absence of vi-
rus-induced secreted IgM resulted in 40% and 50% excess
mortality in mice after infection with influenza A virus (27)
or gastrointestinal bacteria (34), respectively. In compari-
son, the absence of secreted IgM resulted in 100% lethality
in response to WNV infection across a wide (4 log) range
of inoculating doses.
The role of natural IgM in protection against viral in-
fection remains controversial. Reconstitution experiments
demonstrated that IgM that was induced after virus infec-
tion was sufficient to confer protection against WNV,
whereas natural IgM provided no protection. These re-
sults agree with our previous observations with wild-type
and B cell–deficient mice (11): induced IgM prevented
mortality in wild-type mice and delayed mortality in B
cell–deficient mice, whereas natural IgM had no effect on
survival time or rate in B cell–deficient mice. These re-
sults contrast with prior reconstitution experiments with
other pathogens as follows: transfer of natural IgM con-
ferred protection against influenza A (27) and vesicular
stomatitis (26) viruses, and peritonitis induced by cecal li-
gation and puncture (34). Despite our negative data, we
speculate that natural IgM may still function to link the
innate and adaptive immune responses against WNV (24).
However, unlike other pathogens, administration of natu-
ral IgM alone does not adequately control WNV infection
nor compensate for the production of antigen-triggered
induced IgM.
Compared with congenic wild-type mice, no significant
difference in WNV infection was observed in sIgM / 
mice during the first 2 d after infection. However, by 4 d
after infection, markedly higher levels of infectious virus
and viral RNA were detected in the serum of sIgM / 
mice compared with wild-type mice. Thus, the early anti-
WNV IgM response functions, in part, to limit infection by
preventing hematogenous spread. Indeed, the enhanced
viremia and absence of induced IgM correlated with higher
WNV viral burdens in peripheral and CNS tissues at differ-
ent times after infection. Importantly, significantly higher
viral burdens were observed in the kidneys of sIgM / 
mice at day 6 after infection, a time that precedes the de-
velopment of specific anti-WNV IgG antibodies in wild-
type mice. The induction of specific IgM against WNV ap-
peared to directly limit spread to peripheral nonlymphoid
organs. Although IgM could inhibit WNV dissemination
early in the course of infection by preventing virus attach-
ment and entry or by binding C1q and directing comple-
ment-mediated lysis of viral particles (24, 43), the experi-
ments with the H5.46 monoclonal IgM antibody suggest
that the neutralizing activity of IgM confers protection.
The experiments with H5.46 also suggest that IgM binding
to WNV in vivo may not result in clinically significant
complement-mediated lysis of viral particles, results that
agree with in vitro studies that showed that in the presence
of complement, nonneutralizing IgM facilitated rather than
inhibited viral infection in macrophages, presumably by
enhancing viral entry through complement receptor 3 (55,
56). Based on these experiments, we conclude that one
critical function of induced IgM is to limit WNV infection
by neutralizing virus before the development of an adaptive
IgG response.
Nonetheless, the lack of secreted anti-WNV IgM may
predispose to lethal infection by additional mechanisms. In
addition to neutralizing pathogens in circulation (24, 26,
28), IgM inhibits infection by directly enhancing phagocy-
tosis in lymphoid tissue (30), activating complement (27,
32, 43), and by priming the adaptive immune response
(24). Indeed, some of our data suggest that secreted IgM
against WNV contributes to the priming of the adaptive
immune response. Despite the differences in viremia be-
tween wild-type and sIgM /  mice that were observed at
day 4 after infection, the levels of virus detected in the
brain at day 6 were not significantly different; thus, en-
hanced viremia was associated with but did not directly
correlate with increased CNS viral burden. In addition, by
day 8 after infection, a time when  10–20-fold higher lev-
els of WNV were observed in the CNS of sIgM /  mice,
differences in the anti-WNV IgG response were observed:
decreased levels of anti-WNV IgG were consistently de-
tected in the sIgM /  mice. These results agree with others
that have observed blunted IgG levels in response to viral
or protein antigens in mice that lack secreted IgM (27, 33).
Because virus eradication in neurons may depend on spe-
cific IgG (47, 57), the depressed specific IgG response in
sIgM /  mice may contribute to WNV spread in the CNS
and injury of neurons.
The importance of induced IgM early in the course of
WNV infection was confirmed in wild-type mice by pro-
spective analysis. Mice that had high ( 1:45) anti-WNV
IgM titers at day 4 after infection had an improved (70% for
IgMhi vs. 40% overall) survival rate. More dramatically,
mice that had low ( 1:25) anti-WNV IgM titers at day 4
after infection uniformly died. Thus, the absence of a
strong anti-WNV IgM early in the course of infection, by
itself, predicted mortality. To our knowledge, this is the
first work that definitively demonstrates that a depressed or
delayed IgM response against a pathogen in wild-type ani-
mals is an independent risk factor for poor outcome. A re-
cent retrospective clinical analysis supports an important
role of IgM in flavivirus infections: low levels of anti–Japa-
nese Encephalitis virus IgM antibody were an independent
risk factor for neurological disease in humans (22). Al-
though IgM appears to have an important function in lim-
iting WNV infection, it is clear from published works (9–
11, 58) that other aspects of the innate (e.g., interferon andIgM Limits Dissemination of WNV Infection 1860
complement) and adaptive (e.g., T cells) immune system
also control WNV infection.
It is intriguing to consider that severe human WNV in-
fection, which is heavily biased toward an elderly and im-
munocompromised population, occurs, in part, because of a
dysfunctional IgM response against WNV early during in-
fection. The elderly frequently have delayed antibody pro-
duction and shortened durations of protective immunity
after viral challenge or immunization (59–61). Although
WNV causes neurological disease, it does so in a small sub-
set of cases. As therapies become available, it will be impor-
tant to target high-risk populations. Natural history studies
in humans are currently being designed to identify both
clinical and laboratory risk factors for severe WNV disease.
Based on the studies presented here, the delayed develop-
ment of specific, neutralizing anti-WNV IgM is likely to be
an independent risk factor for morbidity and mortality.
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